Table 1.
Descriptive characteristics. Patients treated at the Medical University of Vienna comprised the exploratory cohort, while patients treated at partner centers of the Ovarian Cancer Therapy–Innovative Models Prolong Survival (OCTIPS) consortium comprised the validation cohort.
| Parameter | Exploratory Cohort | Validation Cohort |
|---|---|---|
| Number of patients | 155 | 146 |
| Age at surgery (years) | 58.0 (49.0–66.0) | 57.0 (48.8–64.3) |
| FIGO stage (2014) | ||
| II | 6 (3.9%) | 5 (3.4%) |
| III | 132 (85.2%) | 123 (84.3%) |
| IV | 17 (11.0%) | 18 (12.3%) |
| Residual tumor after primary surgery | ||
| Yes | 48 (30.8%) | 50 (34.2%) |
| No | 107 (68.6%) | 96 (65.8%) |
| CA-125 at primary surgery (kU/L) | 558.0 (221.5–1491.3) | 504 (140.5–1301.0) |
| Time to nadir (days) | 103.5 (73.3–161.3) | not available |
| Log growth rate estimate at 1st recurrence | −3.5 (−4.3–−3.1) | −3.4 (−4.1–−3.0) |
| Log decay rate estimate at 1st recurrence | −1.3 (−1.5–−1.1) | −1.0 (−1.1–−0.9) |
| Status at last follow-up | ||
| Alive | 38 (24.5%) | 42 (28.8%) |
| Progression | 4 (2.6%) | not available |
| Intercurrent death | 26 (16.8%) | 18 (12.3%) |
| Cancer-related death | 87 (56.1%) | 78 (53.4%) |
| Duration of follow-up (months) | 53.0 (27.0–85.0) | 46.0 (28.8–71.5) |
| TFST (months) | 15.0 (8.0–25.5) | 14.5 (7.0–23.0) |
| Available | 117 (75.5%) | 113 (77.4) |
| Not available | 38 (24.5%) | 33 (22.6) |
| TSST (months) | 7.0 (2.5–11.5) | 8.0 (3.0–13.0) |
| Available | 73 (47.1%) | 68 (46.6%) |
| Not available | 82 (52.9%) | 78 (53.4%) |
| TFI 2nd to 3rd recurrence (months) | 5.0 (1.0–10.0) | 4.0 (1.0–9.0) |
| Available | 42 (27.1%) | 45 (30.8%) |
| Not available | 113 (72.9%) | 101 (69.2%) |
Values are presented as median (interquartile range) or number (%). CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; TFST, time to first subsequent therapy; TSST, time to second subsequent therapy; TFI, therapy-free interval.